Quince Therapeutics, Inc. (QNCX) - Total Liabilities
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has total liabilities worth $108.84 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Quince Therapeutics, Inc. operating cash flow efficiency to assess how effectively this company generates cash.
Quince Therapeutics, Inc. - Total Liabilities Trend (2017–2024)
This chart illustrates how Quince Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check QNCX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quince Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Quince Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
elumeo SE
XETRA:ELB
|
Germany | €15.03 Million |
|
Trainline Plc
LSE:TRN
|
UK | GBX452.09 Million |
|
Bioatla Inc
NASDAQ:BCAB
|
USA | $47.15 Million |
|
Strategic Energy Resources Ltd
AU:SER
|
Australia | AU$712.03K |
|
Sarthak Metals Limited
NSE:SMLT
|
India | Rs32.81 Million |
|
Concord Medical Services Holdings
NYSE:CCM
|
USA | $5.01 Billion |
|
Patria Private Equity Trust
LSE:PPET
|
UK | GBX229.45 Million |
|
Walker River Resources Corp.
V:WRR
|
Canada | CA$443.96K |
Liability Composition Analysis (2017–2024)
This chart breaks down Quince Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Quince Therapeutics, Inc. (QNCX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 102.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quince Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quince Therapeutics, Inc. (2017–2024)
The table below shows the annual total liabilities of Quince Therapeutics, Inc. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $84.33 Million | -11.34% |
| 2023-12-31 | $95.12 Million | +2767.65% |
| 2022-12-31 | $3.32 Million | -77.35% |
| 2021-12-31 | $14.64 Million | -14.89% |
| 2020-12-31 | $17.20 Million | +93.48% |
| 2019-12-31 | $8.89 Million | +510.30% |
| 2018-12-31 | $1.46 Million | -94.80% |
| 2017-12-31 | $28.00 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more